宫颈癌
HER2/东北
免疫组织化学
癌基因
医学
阶段(地层学)
肿瘤科
内科学
癌症
宫颈癌
组织学
临床意义
病理
生物
细胞周期
乳腺癌
古生物学
作者
Boniface Ndubisi,Sergi Sanz,Lu Li,Edward S. Podczaski,Guy I. Benrubi,Shahla Masood
出处
期刊:PubMed
日期:1998-01-20
卷期号:27 (6): 396-401
被引量:12
摘要
Expression of the HER-2/neu oncogene has been suggested to confer added virulence or aggressive behavior in gynecologic malignancies. The aim of this study is to determine the frequency of HER-2/neu expression in invasive cervical cancer and its impact on survival in women with cervical cancer.Archival tissue from 150 patients with cervical carcinoma was evaluated immunohistochemically for HER-2/neu oncoprotein expression. Survival information was retrieved retrospectively from patients' medical records.The HER-2/neu expression was observed in 34 out of 150 tumors (22%). The HER-2/neu positive tumors exhibited considerable heterogeneity in the distribution of immunoreactive tumor cells. Tumor grade and histology did not influence the pattern or intensity of HER-2/neu expression. There was no statistically significant difference in survival of patients with HER-2/neu positive and those with HER-2/neu negative tumors (P = 0.50). Tumor stage at diagnosis was the only covariate with prognostic significance in patient survival (P < 0.001).Expression of HER-2/neu oncogene is a rare event in cervical cancer. Immunohistochemical detection of HER-2/neu expression is neither a predictor of survival of patients with cervical cancer nor does it identify subgroups of patients at higher risk for recurrence of disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI